|Outcome at mean 0.4–4.6 y||Comparisons||Number of trials (n)||Hazard ratio (95% CI)||NNT (credible interval)|
|*Abbreviations defined in glossary.|
|†Lifestyle interventions included diet, exercise, or both.|
|‡Oral diabetes drugs were acarbose, flumamine, glipizide, metformin, or phenformin.|
|Type 2 diabetes||Lifestyle v placebo†||10 (4452)||0.51 (0.44 to 0.60)||7 (5 to 9)|
|Oral diabetes drug v placebo‡||8 (4580)||0.70 (0.62 to 0.79)||11 (9 to 15)|
|Orlistat v placebo||2 (814)||0.44 (0.28 to 0.69)||6 (5 to 8)|
|Jiangtang bushen v placebo||1 (51)||0.32 (0.03 to 3.07)||Not significant|
Review: lifestyle or pharmacological interventions prevent or delay type 2 diabetes in people with impaired glucose tolerance
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>
EBN Journal Chat
The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries
from Evidence Based Nursing (EBN).
How to participate >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.